JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1999; 33:924-931
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macdonald, P. S.
Right arrow Articles by McCaffrey, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macdonald, P. S.
Right arrow Articles by McCaffrey, D. J.

Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure

Peter S. Macdonald, MBBS, PhD, FRACPa, Anne M. Keogh, MBBS, MD, FRACPa, Christina L. Aboyoun, BAa, Mayanna Lund, MBBS, FRACPa, Raul Amor, MBBS, FRACPa and Dermot J. McCaffrey, MB, MRCPa

a Heart and Lung Transplant Unit, St. Vincent’s Hospital, Sydney, Australia



View larger version (12K):

[in a new window]
  		Figure 1 Cumulative survival stratified according to baseline New York Heart Association (NYHA) class (NYHA classes I to III have been analyzed as a single group).

 


View larger version (14K):

[in a new window]
  		Figure 2 Cumulative freedom from adverse reactions stratified according to baseline New York Heart Association (NYHA) class (NYHA classes I to III have been analyzed as a single group). Solid bar indicates initiation and titration of carvedilol.

 


View larger version (33K):

[in a new window]
  		Figure 3 Change in left ventricular (LV) end-diastolic dimension (solid bar) and end-systolic dimension (hatched bar) after three months of therapy with carvedilol. **p < 0.002, ****p < 0.0001 compared with baseline. Paired data were obtained in 122 New York Heart Association (NYHA) class I–III patients and 41 class IV patients.

 


View larger version (32K):

[in a new window]
  		Figure 4 Change in left ventricular fractional shortening (solid bar) and ejection fraction (hatched bar) after 3 months of therapy with carvedilol. ****p < 0.0001 compared with baseline. Paired data were obtained in 122 New York Heart Association (NYHA) class I–III patients and 41 class IV patients.

 


View larger version (15K):

[in a new window]
  		Figure 5 Change in 6-min walk distance after 3 months of therapy with carvedilol. Open circles = New York Heart Association classes I to III (n = 121); solid circles = class IV (n = 39).

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1999 by the American College of Cardiology Foundation.